The records supplied for "Mark Rubin" contain work from at least three distinct researchers, and any honest author review must flag this before scoring: (1) a prostate cancer molecular pathologist whose work spans AR signaling loss in advanced prostate cancer and early prostate pathology ; (2) a microbiologist working on enterotoxigenic E. coli virulence regulation in controlled human infection ; and (3) a philosopher of science producing metacritical work on preregistration and replication . The OpenAlex lookup for citation metrics failed (HTTP 429), so no quantitative citation profile can be verified here.
Scores shown are the extraction-layer quality ratings of the papers, not independently verified bibliometrics.
The microbiology work is the strongest single record: a controlled human infection design, transparent SRA data deposition, EMSA validation of FNR promoter binding, and explicit acknowledgment that stool RNA mixes host, microbiome, and dietary signals . The prostate cancer cluster shows sustained, mechanistically coherent work on therapy resistance, though the 2021 review declares industry funding (Sanofi-Aventis, Novartis, Janssen, etc.) and patent co-invention on ETS-fusion diagnostics β a financial-incentive consideration, not necessarily a flaw .
The metascience papers score lowest: purely conceptual, no simulation or systematic review, low reproducibility ratings, and self-declared inability to quantify prevalence of the claimed problematic practices . Disconfirming evidence for any of these clusters would be: multi-institutional failure to replicate benign-margin associations for the pathology work; fnr-mutant in vivo transcriptomes unresponsive for the microbiology work; and simulations showing unadjusted conjunction testing does inflate relevant familywise error for the philosophy work.
Confidence note: Because author identity is ambiguous and no citation metrics were retrievable, this review evaluates record clusters rather than a single person. What would resolve it: OpenAlex/ORCID disambiguation and full publication lists per identity.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.